Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581122 | 0.87 | NTMT1 (0.55) | NTMT1F2ACE | |
| SCHEMBL7220733 | 0.77 | TSHR (0.49) | KMT2A | |
| Coumarin SCHEMBL5701811 | 0.74 | NMUR2 (0.45) | NTMT1OPRM1OPRK1 | |
| SCHEMBL5180148 | 0.72 | TAS1R3 (0.40) | OPRM1OPRK1 | |
| SCHEMBL2285648 | 0.72 | PREP (0.48) | F2 | |
| SCHEMBL5702805 | 0.72 | PREP (0.48) | F2 | |
| SCHEMBL15147189 | 0.69 | ACE (0.58) | F2ACEOPRM1OPRK1 | |
| SCHEMBL19681253 | 0.68 | SIRT6 (0.52) | NTMT1F2 | |
| SCHEMBL4416398 | 0.68 | MAOB (0.43) | F2KMT2A | |
| SCHEMBL4416405 | 0.68 | MAOB (0.43) | F2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-08-28 | — | — | US | claimed |
| WO-2013059622-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-04-25 | — | — | WO | claimed |
| US-9925251-B2 | Treatments for Mycobacterium tuberculosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-03-27 | — | — | US | disclosed |
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2014-08-28 | — | — | US | disclosed |
| WO-2013059622-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243255-A1 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS | CLPP, LONP1, CLPX | NTMT1 791/4885F2 4599/4885ACE 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.